Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.

[1]  E. Racine,et al.  A critical review and analysis of ethical issues associated with the artificial pancreas. , 2019, Diabetes & metabolism.

[2]  Grant J. Smith,et al.  The Use of Continuous Glucose Monitoring With Remote Monitoring Improves Psychosocial Measures in Parents of Children With Type 1 Diabetes: A Randomized Crossover Trial , 2018, Diabetes Care.

[3]  R. Beck,et al.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials , 2018, Diabetes Care.

[4]  Janet M. Allen,et al.  Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial , 2018, The Lancet.

[5]  Y. Bao,et al.  Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes , 2018, Diabetes Care.

[6]  R. Hovorka,et al.  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis , 2018, British Medical Journal.

[7]  G. Charpentier,et al.  Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study , 2018, Acta Diabetologica.

[8]  Gregory P. Forlenza,et al.  Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System , 2018, Diabetes Care.

[9]  Eyal Dassau,et al.  Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia , 2017, Diabetes Care.

[10]  Marc D. Breton,et al.  Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study , 2017, Diabetes Care.

[11]  B. Perkins,et al.  Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. , 2017, The lancet. Diabetes & endocrinology.

[12]  Eyal Dassau,et al.  Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial , 2017, Diabetes Care.

[13]  Ahmad Haidar,et al.  Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas, single‐hormone artificial pancreas, or sensor‐augmented pump therapy in adults with type 1 diabetes: An open‐label, randomised, crossover, controlled trial , 2017, Diabetes, obesity & metabolism.

[14]  Roman Hovorka,et al.  Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study , 2017, The lancet. Diabetes & endocrinology.

[15]  Benyamin Grosman,et al.  Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes , 2017, Diabetes technology & therapeutics.

[16]  Bruce A Buckingham,et al.  Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial , 2017, The Lancet.

[17]  Bruce W Bode,et al.  Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. , 2016, JAMA.

[18]  K. Barnard,et al.  Toward Development of Psychosocial Measures for Automated Insulin Delivery , 2016, Journal of diabetes science and technology.

[19]  Howard C. Zisser,et al.  Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report , 2016, Diabetes Care.

[20]  Claudio Cobelli,et al.  2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[21]  Roman Hovorka,et al.  Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.

[22]  David M Maahs,et al.  Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry , 2015, Diabetes Care.

[23]  Tadej Battelino,et al.  MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial , 2014, Diabetes Care.

[24]  D. Klonoff,et al.  Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study. , 2014, Diabetes technology & therapeutics.

[25]  Neil H. White,et al.  A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to <10 Years , 2012, Diabetes Care.

[26]  G. Charpentier,et al.  The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients , 2011, Diabetes Care.

[27]  B. Frier,et al.  Frequency of Severe Hypoglycemia in Patients With Type I Diabetes With Impaired Awareness of Hypoglycemia , 1994, Diabetes Care.